 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimers disease, today announced the presentation of favorable data from its clinical and drug development program for its lead candidate, Trappsol CycloTM. These data are being presented at the 17th Annual WORLDSymposium 2021, a leading medical a 